ENGN Stock Forecast & Price Target

enGene Therapeutics is viewed favorably because detalimogene has a credible path through the accelerated approval process and could fit well in community urology settings where ease of use, lower administration burden, and tolerability matter as much as efficacy. The market opportunity appears meaningful, with management indicating roughly ~$1B in net sales could come from about 10% share or ~2000 patients at parity pricing, while early payer feedback suggests coverage may follow NCCN guideline inclusion. Although the pivotal dataset is still immature, AUA 2026 data showed a 54% CR anytime rate and 25% 12-month CR, and upcoming 4Q26 updates, a pre-BLA meeting, and cohort guidance could further de-risk the story.

enGene Therapeutics is viewed pessimistically because its lead gene-therapy asset still faces substantial clinical, regulatory, and commercialization uncertainty, and prior LEGEND results reportedly fell below expectations on efficacy and durability. The company remains deeply unprofitable, with a net loss of $32.5M in 3Q26 on $34M of operating expenses, while cash, cash equivalents, and marketable securities totaled $266.3M as of July 31, 2026, implying continued heavy burn despite its BLA preparation in 4Q26. Competitive pressure from better-resourced biotech and pharma rivals, plus a likely need for additional equity financing that could dilute shareholders, further weakens the investment case.